

## Policy Tracker Archive

117<sup>th</sup> United States Congress (Q2: April 1st– June 30th, 2022)

Purported Policy Intent	Policy Mechanisms	Proposals	Source
Accountability and Oversight	Manufacturer Transparency	[Pharmaceutical Research Transparency Act of 2022; Introduced 04/07/2022] Require the Director of the NIH to create a publicly available website to serve as a repository of cost data for all applicable drug clinical trials.	<a href="#">Sen. Stabenow (D-MI)</a>
Accountability and Oversight	Manufacturer Transparency	[Biologics Market Transparency Act of 2022; Introduced 05/25/2022] To amend the Federal Food, Drug, and Cosmetic Act to require prompt reports of marketing status by holders of approved applications for biological products, and for other purposes.	<a href="#">Sen. Kaine (D-VA)</a>
Accountability and Oversight	PBM Transparency	[Pharmacy Benefit Manager Transparency Act of 2022; Introduced 05/24/2022] To prevent unfair and deceptive acts or practices and the distribution of incorrect information related to pharmacy benefit management services for prescription drugs, and for other purposes.	<a href="#">Sen. Cantwell (D-WA)</a>
Accountability and Oversight	Provider Transparency	[Expose Hospitals Violating Price Transparency Act; Introduced 06/16/2022] Require publishing of hospitals found to be in noncompliance with the hospital price transparency rule by the Secretary of Health and Human Services.	<a href="#">Sen. Braun (R-IN)</a>
Foster Competition	Incentivize use of biosimilars and generics	[Generic Substitution Noninterference Act; Introduced 04/07/2022] Prohibit manufacturers from directing or providing incentives to a health care provider to request that a drug be dispensed "as written" or "brand name only" when a generic drug or biosimilar product is available.	<a href="#">Rep. Maloney (D-NY)</a>
Foster Competition	Incentivize use of biosimilars and generics	[Advancing Affordable Medicines for Families Act; Introduced 5/26/2022] To require the Government Accountability Office to issue a report on nonprofit pharmaceutical organizations on their potential impact to accelerate the development of new drugs, generic drugs, new biological products, biosimilar products, cell-based therapies, and devices, and on existing barriers to the success of nonprofit pharmaceutical organizations, including the ability of such organizations to obtain tax-exempt status, access to capital, and access to markets	<a href="#">Sen. Rosen (D-NV)</a>

Purported Policy Intent	Policy Mechanisms	Proposals	Source
Foster Competition	Incentivize use of biosimilars and generics	[Enhanced Access to Affordable Medicine Act of 2022; Introduced 06/06/2022] To amend the Federal Food, Drug, and Cosmetic Act to clarify the conditions under which the Secretary of Health and Human Services can approve generic drug applications with labeling temporarily different than the brand name drug, and for other purposes.	<a href="#">Sen. Romney (R-UT)</a>
Foster Competition	Reduce Market Monopoly	[PRICED Act; Introduced 05/18/2022] To amend the Public Health Service Act to shorten the exclusivity period for brand name biological products from 12 to 5 years.	<a href="#">Rep. Schakowsky (D-IL)</a>
Increase price awareness throughout the supply chain	Public disclosure of pricing information	[Plain Prescription Prices Act; Introduced 04/14/2022] Require direct-to-consumer advertisements for prescription drugs and biological products to include accurate and truthful pricing information.	<a href="#">Rep. Williams (D-GA)</a>
Limit Price Inflation	Impose a financial disincentive on manufacturers for drug prices that are increasing faster than inflation.	[Make Medicine Affordable Act; Introduced 04/11/2022] Require manufacturers to provide rebates for Medicare Part B (single source and biological drugs) and Part D drugs that have prices increasing faster than inflation.	<a href="#">Rep. Slotkin (D-MI)</a>
Reduce costs and improve access for patients	Lower OOP costs	[Capping Drug Costs for Seniors Act of 2022; Introduced 04/06/2022] To provide a cap on beneficiary liability under Medicare Part D.	<a href="#">Sen. Warnock (D-GA)</a>
Reduce costs and improve access for patients	Lower OOP costs	[Make Medicine Affordable Act; Introduced 04/11/2022] Establish a manufacturer discount and subsidy program for applicable drugs for Medicare beneficiaries.	<a href="#">Rep. Slotkin (D-MI)</a>
Reduce costs and improve access for patients	Lower OOP costs	[Make Medicine Affordable Act; Introduced 04/11/2022] Establish a maximum monthly cap on cost-sharing payments under prescription drug plans or Medicare Advantage for Medicare beneficiaries.	<a href="#">Rep. Slotkin (D-MI)</a>
Reduce costs and improve access for patients	Lower OOP costs	[Make Medicine Affordable Act; Introduced 04/11/2022] Require appropriate cost-sharing for certain insulin products under Medicare Part D that is equal to the applicable copayment amount under a prescription drug plan or an MA-PD plan, and that is not more than \$35.	<a href="#">Rep. Slotkin (D-MI)</a>
Reduce costs and improve access for patients	Lower OOP costs	[Make Medicine Affordable Act; Introduced 04/11/2022] Establish a program that enables price negotiation with manufacturers and publication of certain high-priced single source drugs so that the maximum fair price of drugs is ensured and impose an excise tax	<a href="#">Rep. Slotkin (D-MI)</a>

Purported Policy Intent	Policy Mechanisms	Proposals	Source
		on sales by manufacturers who don't comply with negotiating a maximum fair price.	